ENT

On January 29, 2021, the Institute for the Hospital Remuneration System (InEK) has published the List of the requests for innovation funding (NUB) that were submitted by the hospitals in 2020. The medical technologies belonging to the cardiovascular, ENT, eHealth, gastrointestinal, neuromodulation, neurovascular, orthopedic, and other technology groups obtained positive status 1.

On November 3, 2020, the Dutch Healthcare Authority (NZa) published the critical features of the first release of the DRG package for the 2022 (RZ22a). Sixteen new procedure codes and three new DRG groups will be implemented.

MTRC has developed three reports on the key market access topics, including innovation funding, health technology assessment and funding frameworks for medical devices. These reports help to understand the relevance of these frameworks to certain types of medical technologies, including ENT technologies. This post provides some key facts about the HTA, funding and innovation payment landscape for ENT devices in Europe.

NICE issued a consultation document about safety and efficacy of balloon cryoablation for Barrett’s oesophagus and squamous dysplasia of the oesophagus and balloon dilation for eustachian tube dysfunction which were considered for Interventional Procedures Guidance in development for public consultation until 20 September 2019.

The reimbursement for the partial surgical removal of enlarged palatal tonsils has now been confirmed. Thus, contract physicians can bill this service from July 1, 2019. A decision to amend the EBM has been taken by the Valuation Committee.

The report presents a summary of reimbursement situation for balloon sinus dilation for chronic sinusitis. Indications include chronic maxillary, frontal and sphenoidal sinusitis. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland.

The report presents a summary of reimbursement situation for cochlear implants for hearing loss. The only reimbursement within public / statutory health insurance systems is considered. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland.